Von Willebrand Disease Clinical Trial
Official title:
International Post-Marketing Surveillance of Willfact-Wilfactin in Patients With Inherited Von Willebrand Disease.
NCT number | NCT01949220 |
Other study ID # | WINGS |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 2014 |
Est. completion date | December 2017 |
Verified date | December 2017 |
Source | Laboratoire français de Fractionnement et de Biotechnologies |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Collect information about WILLFACT or WILFACTIN in their real life clinical use and identify the therapeutic practices in an international environment.
Status | Completed |
Enrollment | 80 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients with inherited von Willebrand disease - Patients treated with WILLFACT or WILFACTIN - Patient or parent/legal representative who has provided written signed and dated informed consent before any data collection. Exclusion Criteria: - Patients who usually do not keep injection log up to date, when treated. |
Country | Name | City | State |
---|---|---|---|
Belgium | Hopital des enfants Reine Fabiola | Antwerpen | |
Belgium | UZA hopital universitaire | Edegem | |
Czechia | University Hospital | Brno | |
Finland | University Central Hospital | Helsinki | |
Germany | Charité Universitätsmedizin | Berlin | |
Germany | GZRR Gerinnungszentrum Rhein/ Ruhr | Duisburg | |
Germany | Universitatsklinikum | Essen | |
Germany | Goethe Universitat | Frankfurt | |
Germany | Medizinische Hochschule Hannover | Hannover | |
Germany | Werlhof-Institut für Hämostaseologie GmbH | Hannover | |
Germany | Universitätsklinikum Schleswig-Holstein | Kiel | |
Germany | Universitatsklinikum | Mainz | |
Germany | Klinikum der Universität | München | |
Greece | Hemophilia center "LAIKO" general hospital | Athens | |
Italy | Centro di Riferimento Regionale per Emofilia e Trombosi | Catania | |
Italy | AOUC- Azienda Ospedaliero-Universitaria Carregi | Firenze | |
Italy | University of Milan | Milan | |
Norway | Oslo University Hospital | Oslo |
Lead Sponsor | Collaborator |
---|---|
Laboratoire français de Fractionnement et de Biotechnologies |
Belgium, Czechia, Finland, Germany, Greece, Italy, Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Documentation of product consumption data | Product consumption (VWF International Units) by analysis of posology, frequency in relation to the severity of bleeding, type of surgery and other clinical situations. | at each follow-up visit, up to 24 months | |
Secondary | Collection and analysis of adverse events and VWF immunological safety | Adverse event (type, seriousness, severity, frequency, outcome), anti VWF-antibody and anti FVIII-antibody. | at each follow-up visit, up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01651468 -
The Effect of the Nutraceutical "Hemofix" on the Coagulation System
|
N/A | |
Active, not recruiting |
NCT00555555 -
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
|
Phase 4 | |
Terminated |
NCT00178542 -
Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
|
N/A | |
Completed |
NCT02552576 -
Study of Voncento® in Subjects With Von Willebrand Disease
|
Phase 4 | |
Recruiting |
NCT02869074 -
Molecular and Clinical Profile of Von Willebrand Disease in Spain
|
||
Completed |
NCT01602419 -
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
|
||
Completed |
NCT01224808 -
Extension Study of Biostate in Subjects With Von Willebrand Disease
|
Phase 3 | |
Withdrawn |
NCT00694785 -
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
|
Phase 2 | |
Completed |
NCT00805051 -
Acquired Von Willebrand Syndrome in Severe Aortic Stenosis
|
N/A | |
Completed |
NCT00168090 -
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
|
Phase 4 | |
Completed |
NCT02246881 -
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
|
Phase 3 | |
Completed |
NCT04657887 -
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
|
||
Withdrawn |
NCT00630448 -
Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)
|
N/A | |
Terminated |
NCT00387192 -
A Study With OPTIVATE® in People With Von Willebrand Disease
|
Phase 3 | |
Completed |
NCT02973087 -
rVWF IN PROPHYLAXIS
|
Phase 3 | |
Completed |
NCT01410227 -
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
|
Phase 3 | |
Completed |
NCT01589848 -
Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador
|
N/A | |
Completed |
NCT00941616 -
Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00557908 -
The Von Willebrand Disease (VWD) International Prophylaxis Study
|
N/A | |
Active, not recruiting |
NCT04953884 -
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
|
Phase 3 |